These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 17009920)
1. Impaired regulation of immune responses in cognitive decline and Alzheimer's disease: lessons from genetic association studies. Chiappelli M; Tumini E; Porcellini E; Licastro F Expert Rev Neurother; 2006 Sep; 6(9):1327-36. PubMed ID: 17009920 [TBL] [Abstract][Full Text] [Related]
2. The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients. Tumini E; Porcellini E; Chiappelli M; Conti CM; Beraudi A; Poli A; Caciagli F; Doyle R; Conti P; Licastro F Hum Psychopharmacol; 2007 Mar; 22(2):75-80. PubMed ID: 17221831 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. Bossù P; Ciaramella A; Salani F; Bizzoni F; Varsi E; Di Iulio F; Giubilei F; Gianni W; Trequattrini A; Moro ML; Bernardini S; Caltagirone C; Spalletta G Brain Behav Immun; 2008 May; 22(4):487-92. PubMed ID: 17988833 [TBL] [Abstract][Full Text] [Related]
4. Microglia and immune activation in Alzheimer's disease. Gordon MN J Fla Med Assoc; 1993 Apr; 80(4):267-70. PubMed ID: 7685046 [TBL] [Abstract][Full Text] [Related]
5. Relationship of the Ubiquilin 1 gene with Alzheimer's and Parkinson's disease and cognitive function. Arias-Vásquez A; de Lau L; Pardo L; Liu F; Feng BJ; Bertoli-Avella A; Isaacs A; Aulchenko Y; Hofman A; Oostra B; Breteler M; van Duijn C Neurosci Lett; 2007 Aug; 424(1):1-5. PubMed ID: 17709205 [TBL] [Abstract][Full Text] [Related]
6. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Cacabelos R Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277 [TBL] [Abstract][Full Text] [Related]
7. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Porcellini E; Calabrese E; Guerini F; Govoni M; Chiappelli M; Tumini E; Morgan K; Chappell S; Kalsheker N; Franceschi M; Licastro F Neurosci Lett; 2007 Apr; 416(1):66-70. PubMed ID: 17284348 [TBL] [Abstract][Full Text] [Related]
8. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. Lee KS; Chung JH; Lee KH; Shin MJ; Oh BH; Hong CH Immunol Lett; 2008 Dec; 121(2):105-9. PubMed ID: 18930766 [TBL] [Abstract][Full Text] [Related]
9. What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review. Ringman JM J Geriatr Psychiatry Neurol; 2005 Dec; 18(4):228-33. PubMed ID: 16306245 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics in Alzheimer's disease. Cacabelos R Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236 [TBL] [Abstract][Full Text] [Related]
11. Genomics of immune molecules: early detection of cognitive decline and new therapeutic interventions. Licastro F Expert Rev Neurother; 2002 Sep; 2(5):639-45. PubMed ID: 19810979 [TBL] [Abstract][Full Text] [Related]
12. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients. Hernanz A; De la Fuente M; Navarro M; Frank A Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509 [TBL] [Abstract][Full Text] [Related]
13. Genetic variation of CYP19 (aromatase) gene influences age at onset of Alzheimer's disease in women. Corbo RM; Gambina G; Ulizzi L; Moretto G; Scacchi R Dement Geriatr Cogn Disord; 2009; 27(6):513-8. PubMed ID: 19478482 [TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of fas gene: relationship with Alzheimer's disease and cognitive decline. Chiappelli M; Nasi M; Cossarizza A; Porcellini E; Tumini E; Pinti M; Troiano L; Franceschi M; Licastro F Dement Geriatr Cogn Disord; 2006; 22(4):296-300. PubMed ID: 16921240 [TBL] [Abstract][Full Text] [Related]
16. Association of SORL1 gene variants with Alzheimer's disease. Kölsch H; Jessen F; Wiltfang J; Lewczuk P; Dichgans M; Teipel SJ; Kornhuber J; Frölich L; Heuser I; Peters O; Wiese B; Kaduszkiewicz H; van den Bussche H; Hüll M; Kurz A; Rüther E; Henn FA; Maier W Brain Res; 2009 Apr; 1264():1-6. PubMed ID: 19368828 [TBL] [Abstract][Full Text] [Related]
17. Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain). Déniz-Naranjo MC; Muñoz-Fernández C; Alemany-Rodríguez MJ; del Carmen Pérez-Vieitez M; Aladro-Benito Y; Irurita-Latasa J; Sánchez-García F Neurosci Lett; 2007 Oct; 427(1):34-8. PubMed ID: 17923322 [TBL] [Abstract][Full Text] [Related]
18. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538 [TBL] [Abstract][Full Text] [Related]
19. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. Del Bo R; Ghezzi S; Scarpini E; Bresolin N; Comi GP J Neurol Sci; 2009 Aug; 283(1-2):66-8. PubMed ID: 19272614 [TBL] [Abstract][Full Text] [Related]
20. Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. Yu JT; Tan L; Ou JR; Zhu JX; Liu K; Song JH; Sun YP Brain Res; 2008 May; 1210():216-22. PubMed ID: 18423577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]